Intel stock extends gains after report of possible U.S. government stake
Investing.com - H.C. Wainwright raised its price target on Editas Medicine (NASDAQ:EDIT) to $5.00 from $3.00 on Friday, while maintaining a Buy rating on the gene editing company’s stock. The upgrade comes as Editas shares have surged over 114% in the past six months, with analyst targets now ranging from $1 to $6 per share, according to InvestingPro data.
The upgrade follows Editas’ announcement that it expects to select its first in vivo lead candidate in September 2025, narrowed from a previous timeline of mid-2025. This candidate will target either hematopoietic stem cells for sickle cell disease and/or beta thalassemia, or hepatocytes for an undisclosed indication. The company maintains a strong financial position with more cash than debt on its balance sheet, though InvestingPro data indicates it’s currently burning through cash rapidly.
For the September-selected candidate, Editas plans to submit an Investigational New Drug application by mid-2026, with first-in-human dosing expected in the second half of 2026. The company anticipates a potential late-stage trial could begin in the second half of 2027.
Management has reiterated plans to nominate and disclose an additional cell/tissue target by the end of 2025, with in vivo proof-of-concept targeted for 2027. This development supports the breadth of the company’s extrahepatic lipid nanoparticle platform.
H.C. Wainwright cited a more favorable R&D and SG&A expense trajectory than expected as factors in its price target increase, along with forward adjustments to its financial model.
In other recent news, Editas Medicine reported its second-quarter 2025 earnings and pipeline updates, which were generally in line with expectations. Following these updates, Baird raised its price target for Editas Medicine to $6.00 from $4.00, maintaining an Outperform rating on the stock. Additionally, Editas Medicine announced amendments to its 2015 Stock Incentive Plan, extending its term to ten years and removing the "evergreen" provision. The amendments also align dividends on restricted stock with the vesting provisions and disallow dividend equivalents on certain stock options.
Meanwhile, NuCana plc has released its 2024 UK Annual Report, detailing the company’s financial performance and strategic initiatives over the past year. The company also announced its Annual General Meeting scheduled for June 27, 2025, as disclosed in a recent SEC filing. These developments provide investors with insights into both companies’ recent activities and strategic directions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.